GNLX:NASDAQ
Genelux Corp
$2.54
arrow_downward
-0.59%(-0.015) 1D
Oct 12, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.59
High
$2.59
Low
$2.51
Mkt. cap
115.15M
Avg. vol.
260.79K
Volume
0.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
Open
$2.59
High
$2.59
Low
$2.51
Mkt. cap
115.15M
Avg. vol.
260.79K
Volume
0.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 month ago
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Consensus Miss Rate
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com